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Objectives: Depressive symptoms and low vitamin D status are common in older persons and may 
be associated, but findings are inconsistent. This study investigated whether 25-hydroxyvitamin D 
(25(OH)D) concentrations are associated with depressive symptoms in older adults, both cross- 
sectionally and longitudinally. Furthermore, it was examined whether physical functioning could 
explain this relationship, to gain a better understanding of the underlying mechanisms. 
Design, Setting, Participants: Data from two independent prospective cohorts of the Longitudinal 
Aging Study Amsterdam were used: an older cohort (≥65 years, N=1282, assessed from 1995-2002) and 
a younger-old cohort (55-65 years, N=737, assessed from 2002-2009). 
Measurements: Depressive symptoms were measured at baseline and after three and six years 
with the Center of Epidemiological Studies Depression Scale. Cross-sectional and longitudinal linear 
regression techniques were used to examine the relationship between 25(OH)D and depressive 
symptoms. The mediating role of physical functioning was examined in the longitudinal models. 
Results: Cross-sectionally, associations were not significant after adjustment for confounders. 
Longitudinally, women in the older cohort with baseline 25(OH)D concentrations up to 75 nmol/L 
experienced 17-24% more depressive symptoms in the following six years, compared to women with 
25(OH)D concentrations >75 nmol/L. Reduced physical performance partially mediated this 
relationship. In men and in the younger-old cohort, no significant associations were observed. 
Conclusions: Older women showed an inverse relationship between 25(OH)D and depressive 
symptoms over time. Partially, this association may be explained by declining physical functioning. 
 
 
















Worldwide, depression is a leading cause of disability, resulting in significant individual and societal 
burden (1). In addition, low 25-hydroxyvitamin D (25(OH)D) concentrations are common, especially 
among older persons (2, 3). Meta-analyses have shown an inverse association between 25(OH)D 
concentrations and depressive symptoms, but findings are inconsistent and longitudinal studies are 
scarce (4, 5). 
A large Italian population-based cohort of older adults found that persons with low baseline 25(OH)D 
had more depressive symptoms after three and six years, compared to persons with higher baseline 
25(OH)D (6). Chan et al. found an inverse cross-sectional, but no prospective association between 
25(OH)D and depressive symptoms in older persons (7), whereas Williams et al. observed the opposite 
pattern (8). Furthermore, older adults with low 25(OH)D had an almost threefold risk of major 
depressive disorder (MDD) after one year, compared to persons with normal 25(OH)D concentrations 
in a population with cardiovascular disease (9). 
Biologically, a link between vitamin D status and depressive symptoms is plausible, due to protective 
functions of vitamin D metabolites in the brain (10-12) and presence of the vitamin D receptor in 
depression-related brain areas such as the hippocampus (13). To better understand the mechanisms 
underlying the presumed association between 25(OH)D and depression, a mediating role of physical 
functioning in this relationship can also be considered. Physical functioning is associated with both 
25(OH)D and depression: low 25(OH)D concentrations were associated with lower and declining 
physical performance (14, 15), and bidirectional cross-sectional and prospective relationships between 
physical functioning and depression have been observed (16-20). 
The present cohort study investigated whether 25(OH)D concentrations are associated with the 
severity (cross-sectionally) and the course and onset (longitudinally) of depressive symptoms in older 
adults. Data from two independent cohorts of the Longitudinal Aging Study Amsterdam (LASA) were 
used (21). Part of this data was also used in a cross-sectional study by Hoogendijk et al. (2), on which 
the present study elaborates. Hoogendijk observed that depressive symptoms (as determinant) were 
associated with lower 25(OH)D in one LASA cohort. The present study additionally investigated a 
second LASA cohort, examined longitudinal associations and investigated whether physical functioning 




independent cohorts, we aimed to provide more insight into the relationship between 25(OH)D and 





Design and study sample 
 
LASA is an ongoing population-based prospective cohort study that investigates the predictors, 
consequences and time course of physical, cognitive, emotional and social functioning in multiple 
cohorts of older adults (21). Participants were recruited from municipality registries in three regions in 
the Netherlands, together comprising a representative sample of the Dutch older population. Every three 
years, LASA participants are invited for interviews and questionnaires. Interviews are conducted at the 
participants’ homes by trained interviewers. 
Data from two LASA cohorts were used. In 1992, 3107 participants aged 55-85 years were included 
in the first LASA cohort (“older cohort”). As 25(OH)D was first assessed in 1995/96, we took this 
second measurement cycle as baseline for this cohort. Participants of ≥65 years who agreed to have an 
additional medical interview (N=1509) were asked to donate a blood sample. Serum 25(OH)D was 
available from 1320 participants. 
The second LASA cohort commenced in 2002/03 with 1002 participants aged 55-65 years 
(“younger-old cohort”). Of the 919 participants who agreed to the medical interview, 739 participants 
had data on 25(OH)D. 
Follow-up time for the present study was six years. Follow-up data were collected at the subsequent 
two measurement cycles: in 1998/99 and 2001/02 (older cohort), and in 2005/06 and 2008/09 (younger-
old cohort). 
All participants gave written informed consent prior to the start of the study. The LASA study was 
approved by the Medical Ethics Committee of the VU University Medical Center (VUmc). Detailed 










The Center for Epidemiological Studies Depression Scale (CES-D) (22) was assessed at baseline, 
three and six years in both cohorts. The CES-D is a widely-used screening instrument that contains 20 
items about depressive symptoms as experienced in the previous week. Scores range from 0-60, with 
higher scores indicating more depressive symptoms. A score of ≥16 is indicative for clinically relevant 
depressive symptoms. The CES-D displays high reliability (23) and good criterion validity (24) in 
several older populations. 
 
 
Blood sampling and measurement of 25(OH)D 
 
Morning blood samples for the assessment of serum 25(OH)D (in nmol/L) were obtained in 1995/96 
(older cohort) and 2002/03 (younger-old cohort). Participants were allowed to have a light breakfast 
without dairy products. Samples were centrifuged and stored at -20°C until 25(OH)D determination in 
1997/98 (older cohort) and 2010/11 (younger-old cohort). The analyses were carried out by the VUmc 
Endocrine Laboratory. A competitive protein-binding assay (Nichols Diagnostics Capistrano, CA, USA; 
interassay coefficient of variation (CV): 10%) was used for the sample determinations in the older 
cohort, whereas a radioimmunoassay (Diasorin, Stillwater, Minnesota, USA; interassay CV: 10%) was 
used for the younger-old cohort. For the statistical analyses of the present study, 25(OH)D was divided 
into four categories using commonly used cutoff values: <30 nmol/L (deficiency), 30-50 nmol/L 
(insufficiency), 50-75 nmol/L and >75 nmol/L (25, 26). 
 
 
Potential effect modifier and confounders 
 
Gender was examined as a potential effect modifier, as previous studies observed different 
associations between 25(OH)D and depressive symptoms in men and women (6, 9). Education level 
(years), smoking habits (never, former, current smoker), alcohol consumption (grams/week, 10g per 
consumption), presence of the most prevalent somatic chronic diseases among Dutch older adults 
(asthma/chronic obstructive pulmonary disease, cardiac disease (myocardial infarction, coronary artery 
  
disease, heart failure, disease of the cardiac valves, arrhythmia), peripheral arterial disease, diabetes 
mellitus, cerebrovascular accident/stroke, osteoarthritis/rheumatoid arthritis, cancer, hypertension, and 





functioning (Mini-Mental State Examination) (27) were obtained during the interviews and 
questionnaires. To control for seasonal variations in 25(OH)D concentrations (28), the blood collection 
dates were dichotomized into winter (October-March) and summer (April-September). Body mass index 
(BMI) was calculated by dividing measured body weight (in kilograms) by measured body height 
squared (in meters). Information on physical activity in the previous two weeks (walking, cycling, 
sports, heavy household activities, in minutes/day, plus the question whether these activities were 




Potential mediating variables 
 
To cover a broad domain of physical functioning, both objective performance tests and self-reported 
functional limitations were examined for their possible mediating role in the association between 
25(OH)D and depressive symptoms. A modified version of the Short Physical Performance Battery 
(SPPB (15, 30)) was used to assess physical performance. The SPPB includes three tests: walking speed 
(walking three meters, turning around and walking back three meters as fast as possible), chair stands 
(standing up from a chair without using hands five times consecutively, as fast as possible) and standing 
balance (standing with one foot directly in front of the other for up to 10 seconds). In the older cohort, 
the total score of the SPPB ranged from 0-12. As the balance test was not administered to the younger-
old cohort at baseline, the SPPB score for this cohort was composed of the walking speed and chair 
stands scores only, resulting in a score range of 0-8. Higher scores indicate better physical performance. 
Functional limitations were measured with six questions assessing common daily activities: climbing 
stairs, cutting toenails, walking five minutes without resting, rising from a chair, (un)dressing and using 
own/public transportation (31). The participants indicated whether they had difficulty performing these 








As the two cohorts differed in age range, assessment period and 25(OH)D assay, analyses were 
conducted separately for both cohorts. All analyses were conducted with SPSS version 22 (SPSS Inc. 
Chicago, IL, USA), except for the mediation analyses, which were conducted with Mplus (version 7.2) 
and R statistical software (version 3.2.5). A double-sided p-value of <.05 was considered statistically 
significant. Baseline characteristics were compared between 25(OH)D categories using Pearson chi 
square tests for categorical variables or non-parametric Kruskal-Wallis tests for skewed continuous 
variables. Cross-sectional and longitudinal non-response analyses comparing included and excluded 
participants were conducted with Pearson chi square tests for categorical variables or with non- 
parametric Mann-Whitney tests for skewed continuous variables. 
As the distribution of the CES-D scores was skewed to the right, these scores were log-transformed 
using the formula Ln(1+CES-D score). The four 25(OH)D categories were entered as three dummy 
variables in the regression analyses, with the >75 nmol/L group as reference category. The Bs, standard 
errors (SEs) and confidence intervals (CIs) of the regression analyses were transformed back to obtain 
interpretable ratios (eB = ratio). These ratios reflect the percentage of change in the outcome per one unit 
change in the determinant. As these ratios and resulting percentages were calculated from a log-
transformed scale, note that they do not correspond to the same change in CES-D across all 
CES-D scores: higher scores change more than lower scores. For instance: with a ratio of 1.23 and 
corresponding percentage change of 23%, a CES-D score of 20 changes 4.6 points (23% of 20), 





Multiple linear regression analyses with the 25(OH)D categories as determinants and the CES-D 
score as outcome were conducted. To assess effect modification, gender and interaction terms of the 
25(OH)D categories with gender (25(OH)D dummies * gender) were added to the unadjusted model. 
If an interaction term had a p-value of <.10, stratified analyses for men and women were conducted. If 
no effect modification was present, gender was added as a confounder to the analyses. Adjustments for 
 
 





Model 1; additional adjustments for lifestyle/health confounders (smoking, alcohol consumption, 





To study the course of depressive symptoms over time, linear mixed-models analyses were conducted 
with the 25(OH)D categories at baseline as determinants, the CES-D scores after three years and six 
years as outcome and the baseline CES-D score as covariate. These analyses included participants who 
had baseline 25(OH)D and CES-D data and at least one follow-up CES-D measurement. A random 
intercept was added to the longitudinal CES-D variable to control for dependency of individual measures 
over time. A time-interaction term was added to the models to examine possible differences in the 
association between three and six years of follow-up. 
To study whether 25(OH)D predicts the onset of clinically relevant depressive symptoms over time, 
logistic regression analyses were conducted in a subgroup of participants without depressive symptoms 
at baseline (CES-D <16) and at least one follow-up measurement. The outcome was defined as presence 
of clinically relevant depressive symptoms (CES-D ≥16) in the six-year follow-up period. Models and 
effect modification procedures were similar to the cross-sectional analyses. 
Finally, the possible mediating effect of physical performance and functional limitations in the 
relationship between 25(OH)D and depressive symptoms was examined. To account for the temporal, 
stepwise character of this hypothesized relationship, two longitudinal mediation models were fitted in 
which physical performance and functional limitations after three years of follow-up were considered 
as the mediator variables. Using structural equation modeling, the effect of 25(OH)D on physical 
functioning and the effect of physical functioning on depressive symptoms, adjusted for 25(OH)D, were 
simultaneously modelled. Mediation was examined only in analyses that showed a statistically 
significant relationship between 25(OH)D and depressive symptoms. With these mediation analyses, 
the total effect of 25(OH)D on depressive symptoms was separated into direct and indirect effects. The 
direct effect represents the effect of 25(OH)D on depressive symptoms, adjusted for physical 
functioning, whereas the indirect effect represents the multiplied effects of 25(OH)D on physical 
 
 





effect can be seen as the mediating effect of physical functioning in the association of 25(OH)D with 
depressive symptoms (32). Because of the usually skewed distribution of indirect effects, we used 
95% Monte Carlo simulated confidence intervals (20,000 replications) (33). The mediation analyses 
were performed separately for physical performance and functional limitations and were conducted in 





In additional analyses, both cohorts were pooled to increase the N and to investigate the consistency 
of the findings. Since the cohorts used different 25(OH)D assays, the 25(OH)D values of the older cohort 
(Nichols assay) were calibrated towards the values of the younger-old cohort (Diasorin assay), using the 
formula Diasorin=3.7778+0.8889*Nichols (28). The cross-sectional and longitudinal regression 





Of 1320 participants with a 25(OH)D measurement in the older cohort, 38 participants were excluded 
due to missing CES-D scores, leaving 1282 participants available for analysis. In this cohort, 217 
participants (16.9%) had vitamin D deficiency (25(OH)D <30 nmol/L) and 400 participants (31.2%) had 
insufficient 25(OH)D concentrations (30-50 nmol/L). Clinically relevant depressive symptoms (CES-D 
≥16) were present in 193 participants (15.1%) at baseline, in 202 of 1071 participants (18.9%) at three 
years and in 169 of 853 participants (19.8%) at six years of follow-up. Non-response analyses comparing 
analyzed participants (N=1282) with initially eligible participants who were excluded from the cross-
sectional analyses (N=227) showed that non-respondents were older (U=104475.5, p<.001), less 
educated (U=130516.0, p=.02), smoked more (χ2(2)=8.9, p=.01), drank less alcohol (U=121669.5, 
p<.001), had more depressive symptoms (U=96413.0, p=.01), were less physically active (U=74118.0, 
p<.001), had worse cognitive functioning (U=95058.0, p<.001) and physical performance (U=72670.5, 
 
 
p<.001) and more functional limitations (U=87667.5, p=<.001), compared to included participants. Non-
response analyses comparing participants who were excluded from the longitudinal analyses (N=207) 





excluded participants were more often male (χ2(1)=34.6, p<.001) and had more chronic diseases 
(U=538854.0, p=.01). 
Of the 739 participants with a 25(OH)D measurement in the younger-old cohort, two participants 
were excluded from analysis due to either a very high 25(OH)D concentration (182 nmol/L) or a missing 
CES-D score. Of the resulting 737 participants, 56 participants had vitamin D deficiency (7.6%) and 
243 participants had insufficient vitamin D status (33.0%). Clinically relevant depressive symptoms 
were present in 100 participants (13.6%) at baseline, in 95 of 703 participants (13.5%) after three years 
and in 69 of 648 participants (10.6%) after six years. Cross-sectional non-response analyses in this 
cohort revealed that non-respondents (N=182) smoked more (χ2(2)=14,5, p=.001) compared to included 
participants (N=737). Longitudinal non-response analyses showed that excluded participants (N=33) had 
more depressive symptoms (U=39562.0, p=.04), were more often smokers (χ2(2)=11,3, p=.004) and had 
more functional limitations (U=33340.0, p<.001) compared to included participants (N=704). Table 1 





Table 2 presents the results of the baseline regression analyses. Gender was not an effect modifier 
(p>.10 in both cohorts). In the older cohort, participants with 25(OH)D <50 nmol/L had significantly 
more depressive symptoms compared to participants with 25(OH)D >75 nmol/L (<30 nmol/L: 
ratio=1.25, 95% CI: 1.0-1.5; 30-50 nmol/L: ratio=1.17, 95% CI: 1.0-1.4). However, this association 
was attenuated after adjustment for lifestyle/health variables. Similarly, in the younger-old cohort, no 
statistically significant cross-sectional relationship between 25(OH)D and depressive symptoms was 





In the older cohort, gender was a significant effect modifier for the third 25(OH)D dummy (p=.05), 
 
 
so the mixed-models analyses were stratified for men and women (Table 3). No significant associations 
were observed in men, whereas women in baseline 25(OH)D categories below 75 nmol/L experienced 





nmol/L (adjusted model: <30nmol/L: ratio=1.23, 95% CI:1.02-1.49; 30-50 nmol/L: ratio=1.17, 95% 
CI:1.00-1.37; 50-75 nmol/L: ratio=1.24,95% CI:1.06-1.45). Corresponding to these ratios, participants 
with 25(OH)D concentrations below 30 nmol/L had a 23% higher CES-D score over six years than 
persons with 25(OH)D >75 nmol/L. Similarly, participants with 25(OH)D concentrations of 30-50 
nmol/L had a 17% higher CES-D score over six years, and persons with 25(OH)D concentrations of 50-
75 nmol/L had a 24% higher CES-D score over six years compared to persons with 25(OH)D >75 
nmol/L. 
In the younger-old cohort, gender was not an effect modifier (p>.10). After adjustment for 
lifestyle/health confounders, a significant relationship between baseline 25(OH)D and depressive 
symptoms over time was no longer observed (Table 3). 
Time-interaction terms were not significant in both cohorts (p>.10), indicating that the effect of 
25(OH)D on the course of depressive symptoms did not differ between three and six years of follow- 
up. 
In the logistic regression analysis of the older cohort, gender was an effect modifier for the first and 
third 25(OH)D dummy (p=.05 and .01, respectively). Hence, the analyses were stratified for men and 
women. Similar to the mixed-models analyses, significant associations were observed in women: 
women with 25(OH)D concentrations <30 nmol/L had higher odds of developing clinically relevant 
depressive symptoms over six years, compared to women with 25(OH)D >75 nmol/L (odds ratio (OR) 
in adjusted model: 2.9, p=.04, 95% CI: 1.1-8.0). In men, a significantly lower odds of developing 
depressive symptoms over six years was observed for the group with 25(OH)D concentrations of 50- 75 
nmol/L, compared to the >75 nmol/L group (adjusted OR: 0.4, p=.02, 95% CI: 0.2-0.9). However, due 
to the small number of cases in the stratified analyses, the reliability of these results is uncertain. In the 
younger-old cohort, no associations between 25(OH)D and the onset of depressive symptoms were 
observed (adjusted ORs: 0.7-1.1, p>.6). 
 
 
Mediation of physical functioning 
 
The mediation analyses for physical performance and functional limitations were performed for the 
 
 





(Table 4). The indirect effect (mediation effect) of physical performance was statistically significant 
for the 30-50 nmol/L 25(OH)D category, compared to the reference category of >75 nmol/L (ratio of 
indirect effect: 1.03, bootstrapped 95% CI: 1.0-1.1). The corresponding percentage mediation of 20.6% 
suggests that physical performance after three years partially mediates the longitudinal association 
between 25(OH)D and depressive symptoms. The indirect effects of the other 25(H)D categories of 
physical performance and the indirect effects of functional limitations were not statistically significant, 
but the substantial mediation percentages of the <30 and 30-50 nmol/L categories suggest that physical 






The cross-sectional and longitudinal regression analyses were repeated in the pooled dataset. Cross- 
sectionally, participants in 25(OH)D categories up to 50 nmol/L experienced significantly more 
depressive symptoms than participants with 25(OH)D >75 nmol/L in the adjusted model (<30nmol/L: 
ratio=1.20, 95% CI: 1.03-1.40; 30-50 nmol/L: ratio=1.16, 95% CI: 1.03-1.30; Supplemental Table 
1). Corresponding to these ratios, participants with 25(OH)D <30 nmol/L had a 20% higher CES-D 
score than persons with 25(OH)D >75 nmol/L. Similarly, participants with 25(OH)D concentrations of 
30-50 nmol/L had a 16% higher CES-D score compared to persons with 25(OH)D >75 nmol/L. The 
longitudinal pooled analyses revealed no significant associations between 25(OH)D and depressive 
symptoms in the adjusted models (Supplemental Table 2). Due to multiple cohort differences, these 




As an exploratory sensitivity analysis, we examined whether the results would be different if we 
excluded participants who indicated that their physical activity (confounder, LAPAQ) of the previous 
weeks was not representative for the rest of the year. We repeated the tests for interaction of gender and 
 
 
the cross-sectional and longitudinal regression analyses without these participants (-28.2% and - 31.4% 










This study investigated the baseline and prospective six-year association between 25(OH)D 
concentrations and depressive symptoms in two large population-based cohorts of older adults. Cross- 
sectionally, this association was not significant after adjustment for confounders. However, the 
longitudinal analyses revealed a marked difference between men and women in the older cohort (≥65 
years at baseline): women with 25(OH)D concentrations <75 nmol/L at baseline experienced 17-24% 
more depressive symptoms in the following six years than women with 25(OH)D >75 nmol/L. Low 
physical performance partially mediated this relationship. No such associations were observed in men 
or in the younger-old cohort (55-65 years at baseline). According to Geerlings et al., a change of five 
points in the CES-D score can be regarded as a meaningful change in depressive symptoms (34). Hence, 
it depends on the initial CES-D score whether change in 25(OH)D status is associated with a meaningful 
change in depressive symptoms over six years. Higher initial CES-D scores are associated with more 
relevant change. 
The observed differences between the two cohorts could be explained by the better general health 
status of the younger-old cohort. These participants had higher 25(OH)D concentrations, better physical 
functioning, fewer chronic diseases and were more physically active compared to the older cohort. This 
may have enabled the younger persons to better withstand negative effects of low 25(OH)D on mood. 
On the other hand, the smaller sample size of the younger-old cohort may have limited the power of our 
analyses. 
To increase power and to investigate the consistency of the results, both cohorts were pooled in 
additional analyses. Cross-sectionally, these analyses demonstrated significantly more depressive 
symptoms in persons with lower 25(OH)D concentrations (up to 20%), confirming the consistency of 
the associations in both cohorts. In the longitudinal pooled analyses however, the adjusted associations 
were not significant. By comparing the longitudinal analyses presented in Table 3 and Supplemental 





pooled analyses, especially in the 30-50 and 50-75 nmol/L categories. This may be explained by 
considerable cohort differences regarding health status and assessment periods. Due to cohort 
differences, the results of the pooled analyses should be interpreted with caution. 
In the older cohort, a longitudinal association between baseline 25(OH)D and the course of 
depressive symptoms was observed in women only. This gender difference could be attributable to the 
generally lower 25(OH)D concentrations in women compared to men (25(OH)D <50 nmol/L in 56.9% 
of women and 38.9% of men). Milaneschi et al. found a similar gender difference in the InCHIANTI 
study (6). In contrast, no interaction with gender was observed in the Health ABC study (8). 
It was hypothesized that low vitamin D status would reduce physical functioning, which in turn would 
increase depressive symptoms (14, 15, 18-20). Indeed, we observed partial mediation of the association 
of 25(OH)D with depressive symptoms by physical performance. This provides evidence for a potential 
mediating role of physical functioning in the relationship between low 25(OH)D and increasing 
depressive symptoms. To the best of our knowledge, this explanatory role has not previously been 
investigated prospectively. At most, these variables were treated as confounders in former studies (6-9, 
35). The influence of physical functioning may in fact be an important reason why we did not observe 
significant associations in men and in the younger-old participants. Men in the older cohort had better 
physical performance than women (p<.001). Similarly, participants in the younger-old cohort generally 
had higher physical function scores compared to the older cohort (see Table 1). It can be speculated that 
having adequate physical functioning may act as a ‘buffer’ to safeguard older persons from the negative 
impact of low 25(OH)D on their mood. It should be noted that this mediating role of physical functioning 
is still exploratory and should be confirmed by other studies. 
Hoogendijk et al. partly used the same data as the present study and did find a significant cross- 
sectional association between depression status and 25(OH)D concentrations (2). This disparity can be 
explained by their use of different confounders and different operationalization of depression. 
Hoogendijk categorized depression status into ‘no depression’ (CESD <16), ‘minor depression’ (CESD 
≥16) and ‘MDD’ (diagnosis after psychiatric interview) and analyzed it as determinant instead of an 
outcome. We chose not to use the MDD variable as outcome, because the number of participants with 




The present study combines several strengths. The use of data from two large, population-based, 
independent cohorts with a long follow-up increases the value and generalizability of our results. In 
addition, we studied the influence of 25(OH)D on the severity, course and onset of depressive symptoms 
using both cross-sectional and longitudinal analysis techniques, adjusted for relevant confounders. By 
studying 25(OH)D at baseline, physical functioning after three years and depressive symptoms over six 
years, we explored the potential mediating role of physical functioning longitudinally. This method 
takes into account the temporal character of the underlying mechanism. To the best of our knowledge, 
this is the first study that explored physical functioning as a possible mediating factor in the relationship 
between vitamin D status and depressive symptoms. 
Nevertheless, this study also has some limitations. Serum 25(OH)D was only measured at baseline, 
although it was shown that 25(OH)D concentrations are relatively stable over time (28, 36). 
Furthermore, as depressive symptoms were measured only once every three years, we did not have 
information about intermediate time points. Due to the fluctuating nature of depression, we may have 
missed episodes of depressive symptoms. Unfortunately, some potential confounders were not measured 
in the LASA measurement cycles that we used. Due to this, we were unable to adjust for variables such 
as diet and vitamin D supplement use, possibly resulting in residual confounding. Furthermore, over 
99% of LASA participants are Caucasian (28) which may have limited the generalizability of our 
finding to other ethnicities, as evidence suggests that polymorphisms of the 
vitamin D binding protein and hence bioavailability of vitamin D differs between ethnicities.  
The non-response analyses showed that included participants were healthier than excluded persons, 
which may limit generalizability. In addition, the physical activity measure (LAPAQ) only gives 
information about activities in the previous two weeks, and no information about the longer-term habitual 
activity pattern of the participants. Therefore, we conducted a sensitivity analysis without participants 
who indicated that their activities were not representative for the previous year. Results of these analyses 
were similar to the regular analyses. Although this suggests that lack of information on past-year 





habitual physical activity may still be a potential confounding factor. Finally, cohort differences, such 
as different time periods and 25(OH)D assays, may have compromised the comparability of the two 
cohorts. 
In conclusion, this study showed that older women with 25(OH)D concentrations below 75 nmol/L 
at baseline experienced 17-24% more depressive symptoms over six years, compared to women with 
25(OH)D concentrations >75 nmol/L. This relationship may be partially explained by reduced physical 
functioning. To the best of our knowledge, this longitudinal mediating role of physical functioning has 
not been studied before. Our results suggest that having 25(OH)D concentrations >75 nmol/L and 
adequate physical functioning is especially important for the mental health of older women. Randomized 
controlled trials investigating both vitamin D supplementation and behavioral interventions to improve 
physical functioning should examine the causality of these associations further, which may aid treatment 
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Table 1. Baseline characteristics of the two LASA cohorts. 
Older cohort (N=1282)    Younger-old cohort (N=737)  

























 p p 
Depressive symptoms: 
 
CES-D score a 
 



















































Women b 135 (62.2) 240 (60.0) 201 (46.3) 83 (35.9) <.001 28 (50.0) 135 (55.6) 158 (51.0) 78 (60.9) .39 

























Education (years) a 9 [6-11] 9 [6-11] 9 [6-11] 9 [6-11] .04 11 [7-15] 10 [9-12] 10 [9-11] 10 [9-11] .44 
Season of blood collection: b 
Winter 
Summer 








































































Alcohol consumption (gr/wk) a 10 [0-70] 20 [0-70] 30 [5-120] 60 [10-210] <.001 60 [5-210] 70 [20-200] 70 [30-210] 70 [45-210] .23 





























Cognitive functioning (MMSE) a 27 [24-28] 28 [26-29] 28 [26-29] 28 [27-29] <.001 28 [26-29] 28 [27-29] 28 [27-29] 28 [27-29] .09 

























Physical performance a, c 6 [2-8] 7 [5-9] 9 [7-10] 9 [8-11] <.001 6 [4-7] 6 [5-7] 6 [5-7] 6 [5-8] .01 
Functional limitations 2 [0-4] 1 [0-3] 0[0-2] 0 [0-1] <.001 0 [0-2] 0 [0-1] 0[0-0] 0 [0-1] <.001 
 
Values are displayed as N (%) for categorical variables or as median [interquartile range] for skewed continuous variables. a Differences between 25(OH)D categories tested with 
Kruskal-Wallis test; b Differences between 25(OH)D categories tested with Pearson Chi-square test, p-value represents p for trend; c The physical performance score ranges from 0-12 






Table 2. Cross-sectional associations between 25(OH)D and depressive symptoms in the two LASA cohorts. 
 
Older cohort     Younger-old cohort   
  Model 1  Model 2  Model 1  Model 2  







t (df) p  Ratioa 
 
(SE) 
t (df) p Ratioa 
 
(SE) 
t (df) p 











































































>75 nmol/L Ref   Ref    Ref   Ref   
 
a As the outcome variable was ln(1+CESD), Bs and SEs were transformed back to normal scale to obtain interpretable ratios. 
 
Analyzed with multiple linear regression analysis. Model 1: adjusted for age, gender, education and season. Model 2: additionally adjusted for 
smoking, alcohol use, BMI, chronic diseases, cognitive functioning and physical activity. 25(OH)D: 25-hydroxyvitamin D; CES-D: Center for 






Table 3. Longitudinal associations between 25(OH)D and depressive symptoms in the two LASA cohorts; older cohort stratified for gender. 
 
Older cohort       Younger-old cohort   
   Women     Men     Total sample   
 Model 1  Model 2  Model 1  Model 2  Model 1  Model 2  




















































































































































>75 nmol/L Ref 
  Ref   Ref   Ref   Ref   Ref   
a As the outcome variable was ln(1+CESD), Bs and SEs were transformed back to normal scale to obtain interpretable ratios. 
 
Analyzed with linear mixed-models analysis, with the CES-D score after 3 and 6 years as outcome and baseline CES-D as covariate. Model 1: adjusted for age, (gender,) education and season. 
Model 2: additionally adjusted for smoking, alcohol use, BMI, chronic diseases, cognitive functioning and physical activity. 25(OH)D: 25-hydroxyvitamin D; CES-D: Center for 






Table 4. Mediation effects of physical functioning (after three years) in the longitudinal association between baseline 
25(OH)D and depressive symptoms over six years in women of the older LASA cohort. 
Physical performance Functional limitations 
Serum 25(OH)D Indirect effect a 95% CI b % mediationc Indirect effect a 95% CI b % mediationc 
<30 nmol/L 1.03 0.99 - 1.07 12.4 1.04 0.99 - 1.09 16.7 
30-50 nmol/L 1.03* 1.00 - 1.07 20.6 1.02 0.99 - 1.06 13.3 
50-75 nmol/L 1.01 0.98 - 1.04 3.3 1.02 0.98 - 1.05 7.4 
>75 nmol/L Ref   Ref   
 
As the outcome variable was ln(1+CESD), the Bs and confidence intervals of the indirect effects were transformed back to normal 
scale to obtain interpretable ratios. Mediation analyses were performed in the adjusted Model 2. 25(OH)D: 25-hydroxyvitamin D; 
CI: confidence interval. 
a The indirect effect is the mediating effect of physical functioning on the association between 25(OH)D and depressive symptoms. 
It represents the multiplied effects of 25(OH)D on physical functioning and physical functioning on depressive symptoms, adjusted 
for 25(OH)D. 
b Bootstrapped confidence intervals with Monte Carlo simulation. 
 
c Percentage mediation calculated by (indirect effect / total effect)*100. Total effects are displayed in Table 3. 
 









SUPPLEMENTAL DIGITAL CONTENT 1: 
 
 
Supplemental Table 1. Cross-sectional associations between 25(OH)D and depressive symptoms in the 
pooled analysis of the two LASA cohorts. 
Pooled cohort 
  Model 1   Model 2  
Serum 25(OH)D Ratioa (SE) t (df) p Ratioa (SE) t (df) p 
<30 nmol/L 1.33 (1.08) 3.50 (2006) <.001 1.20 (1.08) 2.30 (1962) .022 
30-50 nmol/L 1.21 (1.06) 3.22 (2006) .001 1.16 (1.06) 2.55 (1962) .011 
50-75 nmol/L 1.04 (1.06) 0.72 (2006) .473 1.03 (1.06) 0.58 (1962) .563 
>75 nmol/L Ref 
  Ref   
a As the outcome variable was ln(1+CESD), Bs and SEs were transformed back to normal scale to obtain interpretable ratios. 
Analyzed with multiple linear regression analysis. Model 1: adjusted for age, gender, education, season and cohort. Model 
2: additionally adjusted for smoking, alcohol use, BMI, chronic diseases, cognitive functioning and physical activity. 








SUPPLEMENTAL DIGITAL CONTENT 2: 
 
 
Supplemental Table 2. Longitudinal associations between 25(OH)D and depressive symptoms in the pooled analysis of the two LASA cohorts, stratified for gender. 
 
Women     Men   
 Model 1  Model 2  Model 1  Model 2  
Serum 25(OH)D Ratioa (SE) t (df) p Ratioa (SE) t (df) p Ratioa (SE) t (df) p Ratioa (SE) t (df) p 
<30 nmol/L 1.16 (1.09) 1.82 (973) .069 1.06 (1.09) 0.66 (949) .51 1.24 (1.10) 2.12 (830) .034 1.19 (1.11) 1.73 (808) .085 
30-50 nmol/L 1.09 (1.06) 1.47 (919) .14 1.02 (1.06) 0.29 (897) .77 0.98 (1.07) -0.26 (784) .80 0.98 (1.07) -0.35 (769) .72 
50-75 nmol/L 1.08 (1.06) 1.37 (917) .17 1.06 (1.06) 1.09 (897) .28 0.99 (1.06) -0.14 (786) .89 0.99 (1.06) -0.22 (769) .83 
>75 nmol/L Ref 
  Ref   Ref   Ref   
a As the outcome variable was ln(1+CESD), Bs and SEs were transformed back to normal scale to obtain interpretable ratios. 
 
Analyzed with linear mixed-model analysis, with the CES-D score after 3 and 6 years as outcome and baseline CES-D as covariate. Model 1: adjusted for age, education, season and 
cohort. Model 2: additionally adjusted for smoking, alcohol use, BMI, chronic diseases, cognitive functioning and physical activity. 25(OH)D: 25-hydroxyvitamin D; CES-D: Center for 
Epidemiological Studies Depression Scale. 
